Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.
Horwitz SM, Nirmal AJ, Rahman J, Xu R, Drill E, Galasso N, Ganesan N, Davey T, Hancock H, Perez L, Maccaro C, Bahgat A, Marzouk E, Cathcart E, Moskowitz A, Noy A, Kumar A, Jacobsen E, Fisher DC, Mehta-Shah N, Kim YH, Khodadoust M, Kotlov N, Nikitina A, Kudryashova O, Zubareva V, Zornikova K, Shin N, Sorokina M, Degryse S, Postovalova E, Bagaev A, Hosszu K, McAvoy D, Boelens JJ, Wu W, Ciantra Z, Appelt JW, Trevisani C, Amaka S, Weinstock DM, Vardhana SA. Horwitz SM, et al. Among authors: amaka s. Nat Med. 2024 Dec;30(12):3778. doi: 10.1038/s41591-024-03404-w. Nat Med. 2024. PMID: 39548313 No abstract available.
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.
Horwitz SM, Nirmal AJ, Rahman J, Xu R, Drill E, Galasso N, Ganesan N, Davey T, Hancock H, Perez L, Maccaro C, Bahgat A, Marzouk E, Cathcart E, Moskowitz A, Noy A, Kumar A, Jacobsen E, Fisher DC, Mehta-Shah N, Kim YH, Khodadoust M, Kotlov N, Nikitina A, Kudryashova O, Zubareva V, Zornikova K, Shin N, Sorokina M, Degryse S, Postovalova E, Bagaev A, Hosszu K, McAvoy D, Boelens JJ, Wu W, Ciantra Z, Appelt JW, Trevisani C, Amaka S, Weinstock DM, Vardhana SA. Horwitz SM, et al. Among authors: amaka s. Nat Med. 2024 Sep;30(9):2517-2527. doi: 10.1038/s41591-024-03076-6. Epub 2024 Jun 17. Nat Med. 2024. PMID: 38886623 Clinical Trial.
Targeting Oxidative Stress Mechanisms to Treat Alzheimer's and Parkinson's Disease: A Critical Review.
Aborode AT, Pustake M, Awuah WA, Alwerdani M, Shah P, Yarlagadda R, Ahmad S, Silva Correia IF, Chandra A, Nansubuga EP, Abdul-Rahman T, Mehta A, Ali O, Amaka SO, Zuñiga YMH, Shkodina AD, Inya OC, Shen B, Alexiou A. Aborode AT, et al. Among authors: amaka so. Oxid Med Cell Longev. 2022 Jul 31;2022:7934442. doi: 10.1155/2022/7934442. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 35958022 Free PMC article. Review.
OMICs Technologies for Natural Compounds-based Drug Development.
Aborode AT, Awuah WA, Mikhailova T, Abdul-Rahman T, Pavlock S, Kundu M, Yarlagadda R, Pustake M, Correia IFDS, Mehmood Q, Shah P, Mehta A, Ahmad S, Asekun A, Nansubuga EP, Amaka SO, Shkodina AD, Alexiou A. Aborode AT, et al. Among authors: amaka so. Curr Top Med Chem. 2022 Oct 31;22(21):1751-1765. doi: 10.2174/1568026622666220726092034. Curr Top Med Chem. 2022. PMID: 35894473 Review.
Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.
Wu W, Nelson GM, Koch R, Donovan KA, Nowak RP, Heavican-Foral TB, Nirmal AJ, Liu H, Yang L, Duffy J, Powers F, Stevenson KE, Jones MK, Ng SY, Wu G, Jain S, Xu R, Amaka S, Trevisani C, Donaldson NL, Hagner PR, de Leval L, Gaulard P, Iqbal J, Thakurta A, Fischer ES, Adelman K, Weinstock DM. Wu W, et al. Among authors: amaka s. Blood. 2022 Mar 31;139(13):2024-2037. doi: 10.1182/blood.2021014701. Blood. 2022. PMID: 34936696 Free PMC article.